Back to Search
Start Over
The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the 'Rete Ematologica Lombarda'
- Publication Year :
- 2016
- Publisher :
- Elsevier Ltd, 2016.
-
Abstract
- 5-Azacytidine is an effective therapy in high risk MDS and oligoblastic AML. This "real life" analysis was made on 185 patients treated with 5-azacytidine in 10 centers afferent to REL ("Rete Ematologica Lombarda"), a network in Lombardia region. The aim was to assess the influence of disease and comorbidity risk assessments on the survival. The results confirm the utility of 5-azacitidine in prolonging OS regardless of advanced age and the presence of comorbidities. They also encourage an early treatment since patients with IPSS-R High risk MDS have better outcome with respect to Very High risk ones. According to the IPSS cytogenetic risk, there was no difference in the outcome between Intermediate and High risk patients. Nevertheless, a poorer cytogenetic risk, according to the IPSS-R cytogenetic stratification, negatively influenced the outcome.
- Subjects :
- Adult
Male
Cancer Research
medicine.medical_specialty
Antimetabolites, Antineoplastic
Azacitidine
Disease
Comorbidity
Kaplan-Meier Estimate
Prognostic indice
03 medical and health sciences
Young Adult
0302 clinical medicine
Risk Factors
Internal medicine
medicine
Humans
Young adult
Psychiatry
Aged
Retrospective Studies
Aged, 80 and over
business.industry
Myelodysplastic syndromes
Retrospective cohort study
5-Azacytidine
Hematology
Middle Aged
medicine.disease
Leukemia, Myeloid, Acute
Oncology
ROC Curve
International Prognostic Scoring System
030220 oncology & carcinogenesis
Myelodysplastic Syndromes
High risk myelodysplastic syndrome
Oligoblastic acute myeloid leukemia
Female
business
Risk assessment
030215 immunology
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....4e9c784a5932365497e9234327d18d7e